Objective-Cyclic AMP responsive element-binding protein 3-like 3 (CREB3L3) is a novel candidate gene for dominant hypertriglyceridemia. To date, only 4 kindred with dominant hypertriglyceridemia have been found to be carriers of 2 nonsense mutations in CREB3L3 gene (245fs and W46X). We investigated a family in which hypertriglyceridemia displayed an autosomal dominant pattern of inheritance. Approach and Results-The proband was a 49-year-old woman with high plasma triglycerides (≤1300 mg/dL; 14.68 mmol/L). Her father had a history of moderate hypertriglyceridemia, and her 51-year-old brother had triglycerides levels as high as 1600 mg/dL (18.06 mmol/L). To identify the causal mutation in this family, we analyzed the candidate genes of recessive and dominant forms of primary hypertriglyceridemia by direct sequencing. The sequencing of CREB3L3 gene led to the discovery of a novel minute frame shift mutation in exon 3 of CREB3L3 gene, predicted to result in the formation of a truncated protein devoid of function (c.359delG-p.K120fsX20). Heterozygosity for the c.359delG mutation resulted in a severe phenotype occurring later in life in the proband and her brother and a good response to diet and a hypotriglyceridemic treatment. The same mutation was detected in a 13-year-old daughter who to date is normotriglyceridemic. Conclusions-We have identified a novel pathogenic mutation in CREB3L3 gene in a family with dominant hypertriglyceridemia with a variable pattern of penetrance.
H igh plasma triglyceride concentration is a biomarker of a variety of familial and sporadic metabolic disorders. According to a recent proposed simplified definition 1 of the hypertriglyceridemic states, fasting triglyceride plasma levels <2 mmol/L (175 mg/dL) can be considered normal while triglyceride levels between 2 to 10 mmol/L (175-885 mg/dL) and >10 mmol/L (885 mg/dL) identify subjects with mild to moderate and severe hypertriglyceridemia, respectively. Many common conditions, such as obesity, metabolic syndrome, and pregnancy, alimentary habits, including high alcohol intake, diseases as type 2 diabetes mellitus, hypothyroidism, renal diseases, paraproteinemias, and systemic lupus erythematosus, and some drugs are responsible of mild-to-moderate secondary forms of hypertriglyceridemia. 2 Primary or genetic forms of hypertriglyceridemia include mild-to-moderate and severe forms; mild-moderate hypertriglyceridemia is more frequent than severe hypertriglyceridemia, and recent studies have indicated that this condition may have a polygenic cause with a complex heritability because of the effect of several rare, heterozygous loss-of-function gene variants. 3 The rare severe hypertriglyceridemias are thought to be monogenic autosomal recessive and caused by homozygous or compound heterozygous loss-of-function mutations of few known genes pathophysiologically involved in the intravascular lipolysis of the triglyceride-rich lipoproteins, namely lipoprotein lipase (LPL), apolipoprotein CII (APOCII), apolipoprotein AV (APOAV), glycophosphatidylinositol (GPI)-anchored highdensity lipoprotein-binding protein 1 (GPIHBP1), lipase maturation factor 1 (LMF1), and GPD1. [4] [5] [6] Dominant familial hypertriglyceridemia recently renamed simple primary hypertriglyceridemia is a very common disorder with an estimated frequency of 1:20. 2 The molecular basis of this form seems to be polygenic. 1, 3 The transcription factor cyclic AMPresponsive element-binding protein H (CREB-H, encoded by CRE-binding protein 3-like 3 [CREB3L3]) has been genetically associated with hypertriglyceridemia in humans, 7 and to date, 4 kindred with dominant hypertriglyceridemia associated with CREB3L3 heterozygous mutations (245fs and W46X) have been described. Hypertriglyceridemia because of CREB3L3 pathogenic variants might represent a rare example of monogenic dominant hypertriglyceridemia. 7 Here, we report a family harboring a novel mutation of CREB3L3 gene, which shows a dominant pattern of inheritance and a variable expression of the hypertriglyceridemia trait (Table 1 ).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Phenotype
DNA samples were available from 6 subjects across 2 generations. Lipid profiles of the family members are presented in Figure 1 . The proband (subject II-1) and her brother (II-3) showed moderate hypertriglyceridemia, whereas her sister (II-4) and her daughters (III-1 and III-2) showed a normal lipid profile ( Figure 1 ). Because the triglyceride concentrations in the proband and her brother were >400 mg/dL (> 4.52 mmol/L) and we have not performed direct lowdensity lipoprotein cholesterol measurement, the levels of low-density lipoprotein cholesterol are not provided for these subjects.
The proband's response to treatment, including diet and various regimens of lipid-lowering medication, during the period between 2009 and 2015 is shown in Figure 2 .
During this period, plasma triglyceride levels showed large fluctuations ranging from 150 to 1300 mg/dL (1.69-14.67 mmol/L). These differences were mainly attributed to the poor compliance to low-fat diet and hypolipidemic treatment with ω-3 fatty acids (EPA+DHA, 3 g/d) and fenofibrate (200 mg/d). On the occasion of our fist evaluation, triglyceride plasma levels were 500 mg/dL (5.64 mmol/L); because of the reluctance of the patient to be treated with fibrates, a treatment with 4 g of ω-3 fatty acids supplementation was prescribed.
Under ω-3 fatty acids therapy, she showed an improved lipid profile with triglyceride plasma levels as low as 213 mg/dL after 4 months of treatment (2.40 mmol/L, 43% reduction). For personal reason between February and July 2014, she discontinued the ω-3 fatty acids supplementation with a subsequent relapse of hypertriglyceridemia (plasma triglyceride, 537 mg/dL-6.06 mmol/L). She restarted the treatment and the triglyceride plasma levels decreased to 151 mg/dL (1.7 mmol/L; Figure 2) . ω-3 fatty acids therapy was also prescribed to subject II-3 (proband's brother), but no follow-up data are available.
Genetic Analysis
There were 6 individuals in the family who had both plasma lipids phenotype and DNA available for genotyping. Of these 6 individuals, the proband (II-1) and her brother (II-3) were affected on clinical grounds (triglyceride >175 mg/dL). No functionally relevant mutations in the LPL, APOC2, APOA5, GPIHBP1, and LMF1 genes were detected.
These results and the clinical suspicion of a dominant form of hypertriglyceridemia prompted us to analyze by direct sequencing the whole CREB3L3 gene.
The proband was found to be heterozygous for a novel minute frame shift mutation in exon 3 of CREB3L3 gene, predicted to result in the formation of a truncated protein devoid of function (c.359delG-p.K120fsX20). The presence of the mutation in exon 3 ( Figure 3 ) was confirmed in 3 independent polymerase chain reaction amplifications and direct sequencing. The proband's hypertriglyceridemic brother (II-3) and one of her normotriglyceridemic daughter (III-2) were found to be carriers of the same mutation in the heterozygous state ( Figure 1) .
Even if the c.359delG is predicted to generate a premature stop codon and it is expected to be a rare and deleterious variant, we screened this mutation by direct sequencing in 300 unrelated healthy Italian normolipidemic individuals; the mutation was not found in any of these subjects. Because this analysis was performed in the same ethnic background population of the proband, we cannot draw any certain conclusion about the frequency of the mutation in other ethnic groups.
More, the variant was not reported in the Exome Variant Server repository of the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/), the Exome Aggregation Consortium Website (ExAC, http://exac.broadinstitute.org), and the 1000 Genomes web catalog (http:// www.1000genomes.org), and we did not detect any variant by the analysis of whole CREB3L3 gene in other 7 unrelated patients with moderate hypertriglyceridemia, suggesting that the c.359delG is a rare mutation. In order to try to explain the different lipid phenotype in mutation carriers, we investigated the possible genetic modulating effect on triglyceride levels by APOE genotypes and APOC3 variants. All investigated subjects were carriers of the E2/E3 genotype, but the proband who was E2/E4; direct sequencing of the whole APOC3 gene did not reveal any variant.
Discussion
In this study, we report a novel mutation of CREB3L3 gene, the c.359delG, in 3 related members (mother, daughter, and mother's brother) of a family with a different and variable pattern of penetrance. Heterozygosity for the c.359delG mutation resulted in a severe hypertriglyceridemia phenotype in the proband and her brother with a late in life expression and a good response to diet and hypotriglyceridemic treatments based on fenofibrate and ω-3 fatty acids. The same mutation was detected in the daughter, 13 years old, who to date is normotriglyceridemic.
CREB-H was first identified by Abel et al. 8 CREB-H is a liver-specific bZIP transcription factor that is selectively expressed in the liver and in the small intestine. 7-10 CREB-H binds to the CRE consensus (TGACGTCA) and box-B-like elements present in the promoters of liver-expressed genes. [8] [9] [10] CREB-H regulated genes are involved in acute phase response, 11 iron absorption, 12 and gluconeogenesis. 13 Recent data have suggested a prominent role of CREB-H in the hepatic lipid metabolism, notably in lipogenesis and triglyceride metabolism. The first evidence came from primary mouse hepatocytes incubated with fatty acids. In this experimental setting, fatty acids induced CREB-H mRNA hepatic expression, and this effect was attributed to the involvement of peroxisome proliferator-activated receptor α. 14 Moreover CREB3L3 −/− knockout mice show a 3-fold higher plasma triglyceride levels compared with wild-type mice suggesting a direct involvement of CREB-H in triglyceride metabolism. 7 Additional experiments in CREB3L3 −/− mice demonstrated that CREB-H does not affect hepatic very low-density lipoprotein secretion rate and that LPL activity was reduced indicating that hypertriglyceridemia in these mice is a consequence of an impaired triglyceride clearance from plasma. 7 The infusion of wild-type animals plasma into CREB-H-deficient mice contributed to ameliorate the hypertriglyceridemia phenotype, suggesting that CREB-H effects on triglyceride clearance were mediated by circulating cofactors for LPL. 7 In fact CREB-H controls the expression of genes involved in triglyceride metabolism, including APOC2, APOA4, and APOA5, 7 and the reduced expression of these known cofactors for LPL 15, 16 in CREB3L3 −/− mice could give reasons for the hypertriglyceridemia phenotype. Moreover, CREB-H via peroxisome proliferator-activated receptor α induces FGF21, a liver expressed hormone, which increases insulin sensitivity and reduces plasma triglyceride levels. 17 In early large genome-wide association studies CREB3L3 gene did not emerge as a locus associated with the triglyceride trait. 18 When this gene was resequenced in a cohort of 449 unrelated hypertriglyceridemia subjects, 12 individuals were identified as heterozygous carriers of nonsynonymous or insertional CREB3L3 gene mutations. The analysis of the families of the 4 unrelated nonsense mutation carriers allowed the identification of 7 additional carriers; the triglyceride mean plasma levels of the 11 carriers was significantly higher than those of the noncarriers family members (9.67 versus 1.66 mmol/L, 856 versus 147 mg/dL). 7 Interestingly among the 11 heterozygotes for CREB3L3 nonsense mutations, 3 carriers were normotriglyceridemic, 4 had a mild-to-moderate hypertriglyceridemia, and only 2 had a severe hypertriglyceridemia ( Table 2) . These latter observations might suggest that other factors could contribute to the penetrance of the CREB3L3 genetic defect.
Recently, Johansen et al 3 resequenced CREB3L3 in 413 hypertriglyceridemia subjects and 324 normolipidemic controls and found an enrichment of CREB3L3 rare noncoding, synonymous, and nonsynonymous variants. Three of them (W46X, E240K, and K245Efs374X) were definitely damaging. Unfortunately, it was not reported the severity degree of the hypertriglyceridemia-associated phenotype. The family we described represents the fifth kindred in which a heterozygous frame shift mutation (c.359delG-p.K120fsX20) of CREB3L3 is associated with a severe hypertriglyceridemia phenotype.
Overall 7 rare variants have been reported in CREB3L3 gene so far. 3, 7 Among these, only 2 lead to premature stop codon (W46X and 245fs) and they both have been shown to alter the CREB-H protein function (Table 3 ) and to segregate in pedigrees with hypertriglyceridemia in families. 7 The nonsense mutation reported here is expected to lead to a CREB-H protein with an intermediate size compared with the 2 previously described mutations and although we did not perform functional studies it can be speculated a deleterious effect on function.
Our proband was healthy, and the only relevant clinical feature was the presence of fatty liver detected by ultrasonography. This finding is interesting because of the absence of overweight and insulin resistance. In CREB3L3 knockout mice fed an atherogenic diet, Zhang et al 19 demonstrated the development of hepatic steatosis underlining the role of CREB-H in the regulation of hepatic lipogenesis, lipolysis, and fatty acid oxidation. The proband's daughter (subject III-2) is carrier of the mutation but her triglyceride levels were normal. The analysis of the 5 families (including the present) raises the issue of the penetrance of the heterozygous loss-offunction mutations of CREB3L3 gene. Because the majority of the heterozygotes have a mild-to-moderate hypertriglyceridemia, why do only few heterozygotes develop a severe hypertriglyceridemia form? To answer this question, we can rely only on the few published data. The 2 severe hypertriglyceridemia subjects belonging to 2 unrelated kindred harboring the CREB3L3 245fs mutation were both obese and diabetics; in the CREB3L3 W46X kindred, the proband was overweight but the hypertriglyceridemia form was mild-to-moderate. Among the other 8 sporadic heterozygotes, carriers of CREB3L3 missense mutations, 5 showed a mild-to-moderate form of hypertriglyceridemia (n.2 G105R, n.1 P166L, n.1 D182N, and n.1 E240K) and 3 (n.1 P166L, n.1 V180M, n.1 E240K) a severe form of hypertriglyceridemia. It is worth to note that only 1 P166L heterozygote was diabetic. Overall, based on these sparse clinical information, it is difficult to draw any conclusion about the role as precipitating factors of overweight, obesity, and diabetes mellitus. An accurate follow-up of the identified heterozygotes would significantly contribute to a better understanding of the mechanisms that underlie the clinical expression of the CREB3L3 genetic defect.
The proband of our kindred presented a severe form of hypertriglyceridemia. The response to treatment with fenofibrate (200 mg/d) and ω-3 fatty acids (3 g/d) was excellent, and interestingly when fenofibrate was stopped a mild-tomoderate hypertriglyceridemia developed. This response to the treatment suggests that fenofibrate, as previously demonstrated in vitro, could stimulate the expression of CREB-H via the peroxisome proliferator-activated receptor α pathway in humans. 14 In conclusion, we identified a novel nonsense mutation of CREB3L3 gene, the c.359delG-p.K120fsX20, which was associated with a severe hypertriglyceridemia phenotype and showed a variable penetrance. No functional variants were identified in the other major known hypertriglyceridemiaassociated genes. Moreover, we investigated the possible modulating action of APOE common genotypes and APOC3 gene variants on triglyceride plasma levels. No APOC3 gene variants were identified in all family members; thus, we ruled out an effect on triglyceride levels in mutation carriers. Subjects carriers of the APOE2 allele show higher triglyceride levels compared with the more common APOE3 allele carriers. 20 The 3 mutation carriers (subjects II-1, II-3, and III-2) of this family are carriers of the APOE2 allele and in addition 2 of them (II-3 and III-2) share the same genotype (E2/E3), indicating that the variability of triglyceride plasma levels is not related to APOE genotype. Further studies are warranted to identify putative modulators of the CREB-H partial deficiency. Based on our results and on the other already published observations, searching for CREB3L3 gene mutations should be part of the primary hypertriglyceridemia genetic work-up.
